ES2786078T3 - Métodos y composiciones para tratar depósitos amiloides - Google Patents
Métodos y composiciones para tratar depósitos amiloides Download PDFInfo
- Publication number
- ES2786078T3 ES2786078T3 ES13790429T ES13790429T ES2786078T3 ES 2786078 T3 ES2786078 T3 ES 2786078T3 ES 13790429 T ES13790429 T ES 13790429T ES 13790429 T ES13790429 T ES 13790429T ES 2786078 T3 ES2786078 T3 ES 2786078T3
- Authority
- ES
- Spain
- Prior art keywords
- apoe
- aav
- mammal
- cell
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Biomedical Technology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Biotechnology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Immunology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Toxicology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261648801P | 2012-05-18 | 2012-05-18 | |
| PCT/US2013/031725 WO2013172964A1 (en) | 2012-05-18 | 2013-03-14 | Methods and compositions for treating amyloid deposits |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2786078T3 true ES2786078T3 (es) | 2020-10-08 |
Family
ID=49584137
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES13790429T Active ES2786078T3 (es) | 2012-05-18 | 2013-03-14 | Métodos y composiciones para tratar depósitos amiloides |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20150183850A1 (enExample) |
| EP (1) | EP2850195B1 (enExample) |
| JP (2) | JP6469000B2 (enExample) |
| CN (2) | CN112574964A (enExample) |
| AU (1) | AU2013263346B2 (enExample) |
| BR (1) | BR112014028666B1 (enExample) |
| CA (1) | CA2873890C (enExample) |
| ES (1) | ES2786078T3 (enExample) |
| HK (1) | HK1207109A1 (enExample) |
| IN (1) | IN2014KN02672A (enExample) |
| RU (1) | RU2673484C2 (enExample) |
| WO (1) | WO2013172964A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2975583A1 (en) | 2014-11-14 | 2016-05-19 | Voyager Therapeutics, Inc. | Modulatory polynucleotides |
| WO2016196507A1 (en) | 2015-05-29 | 2016-12-08 | University Of Iowa Research Foundation | Methods of delivery of transgenes for treating brain diseases |
| US20180161395A1 (en) * | 2015-06-12 | 2018-06-14 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Methods and pharmaceutical composition for the treatment of alzheimer's disease |
| JP7161401B2 (ja) * | 2016-04-14 | 2022-10-26 | 公益財団法人神戸医療産業都市推進機構 | アミロスフェロイド（ａｓｐｄ）様構造体及び医薬組成物 |
| IL262784B2 (en) | 2016-05-18 | 2023-10-01 | Voyager Therapeutics Inc | modulatory polynucleotides |
| NZ750291A (en) * | 2016-08-03 | 2021-07-30 | Univ South Florida | Reelin compositions for treatment of neurological disorders |
| CN110121356A (zh) * | 2016-09-02 | 2019-08-13 | 星火治疗股份有限公司 | 治疗cns疾病的方法和载体 |
| EP3309550A1 (en) * | 2016-10-12 | 2018-04-18 | sphingotec GmbH | Method for the detection of apolipoprotein e4 |
| JP7361037B2 (ja) | 2017-10-03 | 2023-10-13 | プリベイル セラピューティクス，インコーポレーテッド | ライソゾーム病の遺伝子治療 |
| AU2018346102B2 (en) | 2017-10-03 | 2023-05-11 | Prevail Therapeutics, Inc. | Gene therapies for lysosomal disorders |
| JP7616995B2 (ja) * | 2018-11-28 | 2025-01-17 | プリベイル セラピューティクス，インコーポレーテッド | 神経変性疾患のための遺伝子治療 |
| MX2022004524A (es) * | 2019-10-16 | 2022-07-21 | Univ Cornell | Tratamiento génico para la enfermedad de alzheimer. |
| KR20230020946A (ko) * | 2020-03-31 | 2023-02-13 | 누오-베타 파마슈티컬 테크놀로지 (상하이) 씨오., 엘티디. | 중수소화 옥소페닐아르신 화합물 및 이의 용도 |
| CN116670291A (zh) * | 2020-11-25 | 2023-08-29 | 普利维尔治疗公司 | 用于神经退行性疾病的基因疗法 |
| US20250297279A1 (en) * | 2021-12-15 | 2025-09-25 | Genans Biotechnology Co., Ltd | Recombinant aav vectors and use thereof |
| CN116063405B (zh) * | 2022-09-27 | 2025-08-29 | 广州译码基因科技有限公司 | 可提高AAV病毒包装能力的衣壳蛋白突变体MutC及其应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5589154A (en) * | 1994-11-22 | 1996-12-31 | Rutgers, The State University Of New Jersey | Methods for the prevention or treatment of vascular hemorrhaging and Alzheimer's disease |
| US6436996B1 (en) * | 1997-09-30 | 2002-08-20 | Duke University | Modulation of nitric oxide production |
| US6855314B1 (en) | 2000-03-22 | 2005-02-15 | The United States Of America As Represented By The Department Of Health And Human Services | AAV5 vector for transducing brain cells and lung cells |
| US6468524B1 (en) | 2000-03-22 | 2002-10-22 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | AAV4 vector and uses thereof |
| GB0322645D0 (en) * | 2003-09-26 | 2003-10-29 | Melacure Therapeutics Ab | Use of antisecretory factor peptides |
| NZ555830A (en) * | 2004-12-15 | 2009-01-31 | Univ North Carolina | Chimeric vectors |
| DK1879623T3 (da) * | 2005-05-02 | 2012-12-17 | Genzyme Corp | Genterapi til rygmarvssygdomme |
| WO2008033375A2 (en) * | 2006-09-14 | 2008-03-20 | Medgenics Ltd. | Long lasting drug formulations |
| HUE027278T2 (en) * | 2007-05-16 | 2016-11-28 | Brigham & Womens Hospital Inc | Treatment of synucleinopathies |
| CA2833912C (en) * | 2010-04-23 | 2021-09-21 | University Of Massachusetts | Aav-based treatment of cholesterol-related disorders |
-
2013
- 2013-03-14 IN IN2672KON2014 patent/IN2014KN02672A/en unknown
- 2013-03-14 JP JP2015512644A patent/JP6469000B2/ja active Active
- 2013-03-14 CN CN202011133829.0A patent/CN112574964A/zh active Pending
- 2013-03-14 CN CN201380038140.1A patent/CN104540952A/zh active Pending
- 2013-03-14 US US14/402,064 patent/US20150183850A1/en not_active Abandoned
- 2013-03-14 HK HK15107526.1A patent/HK1207109A1/xx unknown
- 2013-03-14 RU RU2014151218A patent/RU2673484C2/ru active
- 2013-03-14 AU AU2013263346A patent/AU2013263346B2/en active Active
- 2013-03-14 EP EP13790429.8A patent/EP2850195B1/en active Active
- 2013-03-14 BR BR112014028666-3A patent/BR112014028666B1/pt active IP Right Grant
- 2013-03-14 ES ES13790429T patent/ES2786078T3/es active Active
- 2013-03-14 WO PCT/US2013/031725 patent/WO2013172964A1/en not_active Ceased
- 2013-03-14 CA CA2873890A patent/CA2873890C/en active Active
-
2018
- 2018-11-02 JP JP2018207331A patent/JP2019031564A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP2850195A4 (en) | 2015-12-09 |
| JP6469000B2 (ja) | 2019-02-13 |
| EP2850195A1 (en) | 2015-03-25 |
| CN112574964A (zh) | 2021-03-30 |
| RU2673484C2 (ru) | 2018-11-27 |
| CA2873890C (en) | 2022-12-06 |
| HK1207109A1 (en) | 2016-01-22 |
| IN2014KN02672A (enExample) | 2015-05-08 |
| JP2019031564A (ja) | 2019-02-28 |
| RU2014151218A (ru) | 2016-07-10 |
| BR112014028666B1 (pt) | 2021-12-07 |
| CA2873890A1 (en) | 2013-11-21 |
| EP2850195B1 (en) | 2020-01-22 |
| AU2013263346B2 (en) | 2018-08-23 |
| US20150183850A1 (en) | 2015-07-02 |
| CN104540952A (zh) | 2015-04-22 |
| WO2013172964A1 (en) | 2013-11-21 |
| JP2015520161A (ja) | 2015-07-16 |
| BR112014028666A2 (pt) | 2017-06-27 |
| AU2013263346A1 (en) | 2014-12-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2786078T3 (es) | Métodos y composiciones para tratar depósitos amiloides | |
| ES2920850T3 (es) | Procedimientos y composiciones para el tratamiento de enfermedades oculares genéticas | |
| AU2017318717B2 (en) | Methods and vectors for treating CNS disorders | |
| ES2745470T3 (es) | Partícula de AAV2 que comprende una proteína de la cápside de AAV2 y un vector que comprende un ácido nucleico que codifica una tripeptidilo peptidasa 1 (TPP1) para el tratamiento de lipofuscinosis ceroide infantil tardía (LINCL) en un mamífero no roedor mediante inyección intraventricular o administración icv | |
| ES2949828T3 (es) | Virus AAV/XBP1S-HA, método de terapia génica y uso de este en la optimización y mejora de las capacidades de aprendizaje, memoria y cognitivas | |
| ES2874704T3 (es) | Procedimiento para monitorizar la eficacia de un tratamiento de la enfermedad de Alzheimer con una isoforma de ApoE | |
| JP2019214579A (ja) | 肺に対する特異性を有する新たなペプチド | |
| WO2017075729A1 (es) | Virus aav/upr-plus, proteina de fusion upr-plus, metodo de tratamiento genetico y su uso en el tratamiento enfermedades neurodegenerativas, tales como la enfermedad de parkinson y huntington, entre otras | |
| WO2017059554A1 (es) | Método de tratamiento genético utilizando el virus aav-xbp1s/gfp, y su uso en la prevención y tratamiento de la esclerosis lateral amiotrófica | |
| BR112016011258B1 (pt) | Métodos e composiçôes para o tratamento de depósitos de amiloide | |
| HK1229258B (en) | Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform | |
| HK1229258A1 (en) | Method for monitoring efficacy of treatment of alzheimer's disease with an apoe isoform | |
| JP2025504957A (ja) | アポリポタンパク質ＥのＣ末端フラグメント及びγ－セクレターゼ活性の阻害におけるその応用 | |
| EP4658799A1 (en) | An aav2-vector variant for targeted transfer of genes | |
| KR20240025713A (ko) | 신혈관화 억제제로서 c-형 렉틴인, 레베세틴 |